Cytek Biosciences (CTKB) Assets Average (2021 - 2026)

Cytek Biosciences' Assets Average history runs 6 years deep, the most recent figure standing at $455.3 million for Q1 2026.

• Quarterly Assets Average fell 7.27% year-over-year to $455.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $455.3 million (down 7.27% YoY) and the FY2025 annual result came in at $480.5 million, down 3.31% from the prior year.
• Assets Average was $455.3 million for Q1 2026 at Cytek Biosciences, down from $478.2 million in the prior quarter.
• Across five years, Assets Average topped out at $524.8 million in Q2 2023 and bottomed at $455.3 million in Q1 2026.
• A 5-year average of $495.1 million and a median of $493.3 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average surged 44.92% — and 2026, when it declined 7.27%.
• Cytek Biosciences' Assets Average stood at $509.4 million in 2022, then dropped by 0.48% to $506.9 million in 2023, then slipped by 2.28% to $495.4 million in 2024, then dropped by 3.46% to $478.2 million in 2025, then fell by 4.79% to $455.3 million in 2026.
• Business Quant data shows CTKB's Assets Average at $455.3 million in Q1 2026, $478.2 million in Q4 2025, and $494.1 million in Q3 2025.